Enhancing Genetic Diagnosis for Expectant Parents
Clevergene, a leading genomics company, has obtained the PCPNDT license, marking a significant milestone. The company’s clinical diagnostics arm, The Gene Lab, is now offering a range of cutting-edge genetic tests that promise improved outcomes for expectant parents and those planning pregnancies.
Revolutionizing Prenatal Testing with NIPT
One standout innovation is Non-Invasive Prenatal Testing (NIPT), a groundbreaking technique that uses cell-free DNA from maternal blood to detect chromosomal aneuploidy in fetuses. Clevergene’s NIPT tests can screen for conditions like Down syndrome and Patau syndrome as early as nine weeks of gestation, without posing any risk to the fetus.
Precision with Illumina NovaSeq 6000 Platform
Clevergene’s recent addition of the Illumina NovaSeq 6000 DNA sequencing platform boosts their genetic analysis capabilities. This cutting-edge technology enhances the accuracy and efficiency of their diagnostic processes, ensuring the delivery of sensitive and accurate results in a timely manner.
Comprehensive Genetic Solutions for Families
With a focus on patient outcomes, Clevergene’s Co-Founder & CEO, Tony Jose, emphasizes their commitment to providing sensitive and accurate genetic tests. The Gene Lab is expanding its suite of genomic-based tests to cover a wide range of inherited diseases and cancers, offering comprehensive genetic solutions for families.
Empowering Parenthood with Advanced Genetic Insights
Clevergene, a frontrunner in deep tech genomics, has obtained the PCPNDT license, a crucial validation for its venture into prenatal diagnostics and preimplantation genetic screening.Through The Gene Lab, Clevergene is set to revolutionize the genetic testing landscape, offering a suite of tests designed to empower expectant parents and those planning families.
A Glimpse into Prenatal Precision – NIPT Unveiled
At the forefront of their offerings is the game-changing Non-Invasive Prenatal Testing (NIPT). This remarkable approach harnesses cell-free DNA from maternal blood to detect fetal chromosomal abnormalities, providing insight into conditions like Down syndrome and Edwards syndrome. The innovation’s remarkable accuracy makes it possible to begin screening as early as nine weeks into gestation, presenting no risk to the unborn child.
Unlocking Genetics with Illumina NovaSeq 6000
Recent reinforcement in Clevergene’s arsenal comes from the cutting-edge Illumina NovaSeq 6000 DNA sequencing platform. This advancement propels their capacity for DNA analysis, promising heightened precision and quicker turnaround times. The technology’s implementation underscores Clevergene’s commitment to delivering sensitive and swift genetic analysis to their clients.
Beyond Diagnostics: A Holistic Genetic Vision
Tony Jose, Co-Founder & CEO of Clevergene, underlines the mission to improve patient outcomes through finely tuned genetic tests. The Gene Lab’s expanding repertoire covers not only prenatal diagnostics but also inherited diseases and cancer screening. This all-encompassing approach underscores Clevergene’s dedication to comprehensive genetic solutions for individuals and families.
Also Read: Everything You Need to Know About Oral Cancer Screening